Skip to main content Help with accessibility Skip to main navigation

Lebrikizumab

Indication

Treating moderate to severe atopic dermatitis in people 12 years and over (NICE TA986)

NICE TA986: Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over

Red

Brand:

Nice TA:

986

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Skin

Background

1.1 Lebrikizumab is recommended as an option for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in people 12 years and over with a body weight of 40 kg or more, only if:

  • the atopic dermatitis has not responded to at least 1 systemic immunosuppressant or these treatments are not suitable, and
  • dupilumab or tralokinumab would otherwise be offered, and
  • the company provides it according to the commercial arrangement.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD
BP
CSR
EL
FW
GP
MB
WL
Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 22 - Oct - 2024